

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### The efficacy of Pregabalin compared to placebo in management of acute postoperative pain after anterior cruciate ligament (ACL) reconstruction surgery

#### Protocol summary

##### Study aim

Effectiveness of pregabalin compared to the placebo group in improving pain after anterior cruciate ligament reconstruction surgery in the acute phase, in patients referred to Akhtar Hospital in 1402

##### Design

Two arm parallel group randomized Double-Blind phase 2 trial in 132 patients who undergo ACL reconstruction surgery

##### Settings and conduct

This double-blind study will evaluate the analgesic effect of pregabalin. Participants will randomly assign to receive pregabalin or a different placebo, with both supervising personnel and participants unaware of the method used, and unbiased assessment of pain relief and ensure its delivery. Potential sources of outcome assessor bias will be blinded. The purpose of the careful design of this study is to provide strong evidence for the analgesic effect of pregabalin.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 18-45 year old patients who undergo arthroscopic anterior cruciate ligament reconstruction surgery. Exclusion criteria: (1) any known allergy or contraindication to pregabalin. (2) History of heart, kidney or liver disease. (3) Preoperative use of antidepressants or anticonvulsants. (4) history of drug or alcohol addiction; (5) Nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids use 48 hours before surgery. (6) Meniscus repair or allograft use.

##### Intervention groups

Pregabalin group: single dose of pregabalin 150 mg 2 hours before surgery Placebo group: one dose of placebo before surgery

##### Main outcome variables

Pain measured using Numeric pain scale

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20230809059098N1**

Registration date: **2023-11-29, 1402/09/08**

Registration timing: **registered\_while\_recruiting**

Last update: **2023-11-29, 1402/09/08**

Update count: **0**

##### Registration date

2023-11-29, 1402/09/08

##### Registrant information

##### Name

Emad Kouhestani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2206 9182

##### Email address

emadkouhestani@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-10-23, 1402/08/01

##### Expected recruitment end date

2024-01-21, 1402/11/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

The efficacy of Pregabalin compared to placebo in management of acute postoperative pain after anterior cruciate ligament (ACL) reconstruction surgery

## Public title

Effect of Pregabalin on postoperative pain after anterior cruciate ligament (ACL) reconstruction

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Patients aged 18 to 45 who undergo arthroscopy for anterior cruciate ligament reconstruction in Akhtar Hospital in 1402 are included in the study.

### Exclusion criteria:

Any known allergies or contraindications to pregabalin  
History of heart, kidney or liver disease  
Preoperative use of antidepressants or anticonvulsants  
History of drug or alcohol addiction  
Nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids use 48 hours before surgery  
Patients who underwent meniscus reconstruction or allografts were used

## Age

From **18 years** old to **45 years** old

## Gender

Male

## Phase

2

## Groups that have been masked

- Participant
- Investigator
- Outcome assessor

## Sample size

Target sample size: **132**

## Randomization (investigator's opinion)

Randomized

## Randomization description

In this randomized clinical trial study, patients are placed in each of the two groups according to the simple randomization method in a 1:1 ratio. The assigned group for each person is notified to the surgeon by a sealed letter.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

In this double-blind study, patients are studied with random identification codes assigned to them by the researcher. Patients and the person in charge of data collection are blinded to the type of patient group. Patients will be unaware of which study group they are in. Both intervention and control groups receive similar recommendations. The person in charge of data collection will be unaware of the treatment group of each patient and will record the results only based on the identification code of the people.

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shahid Beheshti University of Medical Sciences

##### Street address

Shariati street

##### City

Tehran

##### Province

Tehran

##### Postal code

199871793

#### Approval date

2023-10-18, 1402/07/26

#### Ethics committee reference number

IR.SBMU.RETECH.REC.1402.346

## Health conditions studied

### 1

#### Description of health condition studied

Pain

#### ICD-10 code

M25.5

#### ICD-10 code description

Pain in joint

## Primary outcomes

### 1

#### Description

Postoperative pain

#### Timepoint

6, 12, 24 hours postoperatively

#### Method of measurement

Numeric pain scale

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: A single dose of pregabalin from Tehran Shimi Company, 150 mg, is taken 2 hours before surgery with a glass of water.

#### Category

Treatment - Drugs

## 2

### Description

Control group: A single dose placebo (capsule containing sucrose with the same shape and color as pregabalin capsule) is taken with a glass of water 2 hours before surgery.

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Akhtar Hospital

**Full name of responsible person**

Emad Kouhestani

**Street address**

Sharifi Manesh street

**City**

Tehran

**Province**

Tehran

**Postal code**

199871793

**Phone**

+98 21 2260 1761

**Email**

emadkouhestani@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Akhtar Hospital Research Center

**Full name of responsible person**

Emad Kouhestani

**Street address**

Sharifi Manesh street

**City**

Tehran

**Province**

Tehran

**Postal code**

1964714953

**Phone**

+98 21 2260 1761

**Email**

emadkouhestani@gmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Akhtar Hospital Research Center

**Proportion provided by this source**

100

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Emad Kouhestani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

Sharifi Manesh street

**City**

Tehran

**Province**

Tehran

**Postal code**

1964714953

**Phone**

+98 21 2260 1761

**Email**

emadkouhestani@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Emad Kouhestani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

Sharifi Manesh street

**City**

Tehran

**Province**

Tehran

**Postal code**

1964714953

**Phone**

+98 21 2260 1761

**Email**

emadkouhestani@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Emad Kouhestani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Orthopedics

**Street address**

Sharifi Manesh street

**City**

Tehran

**Province**

Tehran

**Postal code**

1964714953

**Phone**

+98 21 2260 1761

**Email**

emadkouhestani@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

Collected deidentified IPD, IPD collected for the primary outcome measure only

**When the data will become available and for how long**

Deidentified data will be available starting from May, 2023.

**To whom data/document is available**

People working in academic institutions

**Under which criteria data/document could be used**

No specific condition

**From where data/document is obtainable**

Email Emad Kouhestani to obtain data  
emadkouhestani@gmail.com

**What processes are involved for a request to access data/document**

The process is: 1- Asking a written request contain the main reasons of data importance for the applicant 2- After receiving the request letter, data will be provided in one month.

**Comments**